Pradaxa (also known as Dabigatran Etexilate) is an inactive “parent” drug that relies on the body’s metabolism to eventually manufacture a form of the drug that the body can use as an anti-coagulant, a process that occurs after the drug has been ingested by a patient. Anti-coagulants such as Warfarin […]
Category: Pradaxa
In late 2010, the FDA approved the drug called Pradaxa (dabigatran); manufactured by Boehringer Ingelheim. Pradaxa is a blood thinner and is supposed to be prescribed to patients who suffer from the cardiac disorder atrial fibrillation. Atrial Fibrillation is the most common form of abnormal heart rhythm. Patients who suffer […]
In 2010, the U.S. Food & Drug Administration approved Pradaxa (Dabigatran Etexilate). Pradaxa acts as a blood “thinner” and is promoted to reduce the risk of stroke and blood clots in people with atrial fibrillation. Atrial fibrillation, affecting over two million Americans, occurs when the heart does not beat properly […]
Pradaxa (dabigatran etexilate mesylate), a new oral anticoagulant, achieved Food & Drug Administration (“FDA”) approval on October 19, 2010. One notable advantage of using Pradaxa to replace Warfarin to prevent clot formation is the elimination of INR testing in patients taking Pradaxa. INR is the acronym for International Normalized Ratio, which is used to monitor the effectiveness of anticoagulant such as warfarin.